Alaunos Therapeutics completes acquisition of Velaris Therapeutics
TCRT•Alaunos Therapeutics completed its acquisition of privately held Velaris Therapeutics, adding a pipeline targeting pulmonary arterial hypertension and related cardiopulmonary diseases.
1. Acquisition completed
Alaunos Therapeutics completed its acquisition of privately held Velaris Therapeutics. The deal adds ActRII-Fc ligand traps and complementary biologics targeting signaling imbalances linked to pulmonary vascular remodeling. The transaction was disclosed in a Form 8-K filed on Oct. 13, 2026.
